Iterum Therapeutics plc (ITRMF) EBT (2017 - 2025)

Iterum Therapeutics has reported EBT for 9 years, with the latest figure at -$8.8 million in Q3 2025.

• On a quarterly basis, EBT fell 48.49% year-over-year to -$8.8 million in Q3 2025; TTM through Sep 2025 was -$27.1 million, a 15.29% increase from a year earlier, with the FY2024 full-year figure at -$24.9 million, up 36.95% from the prior year.
• EBT was -$8.8 million for Q3 2025 at Iterum Therapeutics, down from -$6.4 million in the prior quarter.
• The five-year high for EBT was $7.9 million in Q2 2021, with the low at -$98.9 million in Q1 2021.
• Average EBT over 5 years is -$11.6 million, with a median of -$6.4 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: EBT jumped 164.17% in 2021, then plunged 825.12% in 2022.
• Over 5 years, EBT stood at -$4.0 million in 2021, then slipped by 24.38% to -$5.0 million in 2022, then tumbled by 179.88% to -$14.0 million in 2023, then soared by 50.39% to -$6.9 million in 2024, then decreased by 27.72% to -$8.8 million in 2025.
• The last three EBT figures came in at -$8.8 million (Q3 2025), -$6.4 million (Q2 2025), and -$4.8 million (Q1 2025), per Business Quant data.